{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:38:39Z","timestamp":1765438719692,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford\/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford\/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations.<\/jats:p>","DOI":"10.3389\/fmed.2021.752443","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T04:49:02Z","timestamp":1630990142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination"],"prefix":"10.3389","volume":"8","author":[{"given":"Kanchana","family":"Leerunyakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kallapan","family":"Pakornphadungsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonkiat","family":"Suchonwanit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1111\/jdv.17316","article-title":"Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report","volume":"35","author":"Akdas","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15040","article-title":"Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male","author":"Adya","year":"2021","journal-title":"Dermatol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/ijd.15700","article-title":"Pityriasis rosea after mRNA COVID-19 vaccination","volume":"60","author":"Abdullah","year":"2021","journal-title":"Int J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1111\/jdv.17342","article-title":"Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine","volume":"35","author":"Cyrenne","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.12998\/wjcc.v5.i6.203","article-title":"Clinical variants of pityriasis rosea","volume":"5","author":"Urbina","year":"2017","journal-title":"World J Clin Cases."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e13650","DOI":"10.1111\/dth.13650","article-title":"Diagnostic and prognostic values of cutaneous manifestations in COVID-19","volume":"33","author":"Suchonwanit","year":"2020","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.jaad.2020.04.094","article-title":"Cutaneous manifestations in COVID-19: Lessons learned from current evidence","volume":"83","author":"Suchonwanit","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/jmv.26549","article-title":"Human herpesvirus-6,\u22127, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19","volume":"93","author":"Drago","year":"2021","journal-title":"J Med Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e13878","DOI":"10.1111\/dth.13878","article-title":"SARS-CoV-2 as possible inducer of viral reactivations","volume":"33","author":"Ciccarese","year":"2020","journal-title":"Dermatol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D380D8301D","article-title":"Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center","volume":"12","author":"Atzori","year":"2006","journal-title":"Dermatol Online J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jdcr.2018.04.002","article-title":"Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?","volume":"4","author":"Drago","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jdv.12942","article-title":"Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature","volume":"30","author":"Drago","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"253154","DOI":"10.1155\/2015\/253154","article-title":"Leprosy Reaction in Thai Population: A 20-Year Retrospective Study","volume":"2015","author":"Suchonwanit","year":"2015","journal-title":"Dermatol Res Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10103-019-02783-8","article-title":"A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia","volume":"34","author":"Suchonwanit","year":"2019","journal-title":"Lasers Med Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.4081\/dr.2017.7399","article-title":"A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata","volume":"9","author":"Sriphojanart","year":"2017","journal-title":"Dermatol Reports."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/ijd.13061","article-title":"Factors affecting the severity of central centrifugal cicatricial alopecia","volume":"55","author":"Suchonwanit","year":"2016","journal-title":"Int J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000517971","article-title":"Comparative analyses of clinical features, histopathology, and CD123 immunohistochemistry of oral lupus erythematosus, lichen planus, and other lichenoid lesions","author":"Chanprapaph","year":"2021","journal-title":"Dermatology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.752443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T04:49:04Z","timestamp":1630990144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.752443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":18,"alternative-id":["10.3389\/fmed.2021.752443"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.752443","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"article-number":"752443"}}